Why MedTech Companies That Treat Marketing as an Afterthought Are Losing Ground

The Market Has Grown Up. Has Your Commercial Strategy?

I have spent years working alongside marketing and commercial teams in the medical device and diagnostics space, and one pattern I see repeatedly is this: companies invest enormously in their technology and then assume the commercial side will follow naturally. It does not. In 2026, clinical performance is the entry ticket, not the differentiator. The companies gaining real ground are the ones that can articulate value as clearly as they can prove it.

The global medical devices market is on track to grow from USD 586 billion in 2025 to over USD 1 trillion by 2035. The smart diagnostics and monitoring segment alone is projected to reach USD 48.5 billion by 2035, at a CAGR of 12.3%. These are extraordinary numbers, and they mean the competitive intensity in this space is only going to increase. In that environment, a well-funded product with weak market positioning is a serious risk, not just a missed opportunity.

Connected Technology Needs a Connected Commercial Narrative

Software-integrated diagnostics, remote patient monitoring platforms, and imaging tools with embedded analytical capabilities are now the growth edge of the MedTech sector. Over 1,016 FDA-cleared software-driven medical devices exist in the US market as of mid-2025, a number growing rapidly. The companies that built these products have often invested years in clinical validation, but many have not invested proportionally in how they communicate their value to the market.

The commercial challenge is no longer proving that your technology works. It is demonstrating that it delivers measurable clinical and economic outcomes that payers, procurement committees, and clinical decision-makers can act on with confidence. The companies winning this conversation are investing in outcomes-based messaging, health economics frameworks, and content that speaks to the full spectrum of buyer concerns, not just the technical specifications.

I would also push back on any framing that treats this as purely a content or digital marketing issue. It is a strategic positioning issue. If your brand story cannot hold up under scrutiny from a hospital value analysis committee as readily as it resonates with a clinical champion, your commercial pipeline will reflect that weakness sooner or later.

Regulatory Complexity Is a Commercial Variable, Not Just a Compliance Matter

The FDA's evolving oversight of connected health and diagnostic devices, combined with increasingly stringent cybersecurity guidance requirements, is reshaping how MedTech products enter the market. The EU's Medical Device Regulation continues to raise the bar for manufacturers seeking to maintain or grow their European presence. These shifts affect far more than your regulatory team. They affect your entire commercial narrative.

Decision-makers at hospitals, integrated delivery networks, and health systems are routinely including regulatory track record and cybersecurity posture in their procurement criteria. If your marketing does not proactively address these concerns through your content, collateral, and thought leadership program, you are creating a trust gap that a well-prepared competitor will step into.

There is also a timing dimension worth noting. Recent staffing and leadership changes at the FDA have introduced genuine uncertainty into US launch planning for a number of MedTech companies. A carefully constructed market access communication strategy can protect commercial momentum during uncertain review periods by keeping payers, procurement teams, and channel partners engaged and informed throughout the process.

The Buyer Has Changed. Your Messaging Architecture Needs to Reflect That.

The wearable medical technology market is projected to grow at a CAGR of 25.53% through 2030. As devices like continuous glucose monitors become available without a prescription and consumer electronics increasingly overlap with medical-grade tools, the buyer profile for these products is fundamentally shifting. In many categories, you are no longer speaking only to clinicians. You are speaking to patients, caregivers, and retail channel partners at the same time.

This is one of the more complex messaging challenges in the sector, and most internal marketing teams are not resourced to manage it effectively on their own. Your clinical evidence needs to translate into plain-language value propositions that resonate with non-clinical buyers. Your brand needs to hold its credibility across a hospital procurement panel and a direct-to-consumer product page simultaneously. Getting that balance right requires deliberate architecture, not just good creative instincts.

What Stronger Commercial Execution Looks Like in Practice

The MedTech organisations I see generating consistent commercial momentum share a few operating principles. They develop sharply defined value messages for each distinct buyer type in their purchasing process. They invest in thought leadership content that establishes their category credentials before they make a product case. They build digital infrastructure that supports the full buyer journey, from awareness through to procurement justification. And they work with external partners who understand both the clinical substance and the commercial strategy required to bring MedTech products to market well.

At VELLUM, we work with medical device and diagnostics companies across the product lifecycle to build marketing strategies that are clinically credible, commercially sharp, and designed for the realities of a complex buying environment. Whether you are preparing for a product launch, entering a new geography, or rebuilding your commercial foundation after a period of product development focus, we should have a conversation.

Ready to build a commercial strategy that matches the quality of your technology? Contact VELLUM today.

About VELLUM Global

VELLUM is a life sciences-focused marketing agency serving companies across Medical Devices & Diagnostics, Pharmaceuticals & Biologics, OTC & Consumer Health, Cosmetics & Specialty Chemicals, Food & Nutritional Supplements, Laboratory Equipment & Scientific Instruments, CDMOs & Manufacturing Organizations, and Regulatory & Consulting Organizations. We combine strategic intelligence, scientific credibility, and marketing craft to help our clients build meaningful brands, generate qualified leads, and grow commercially in one of the world's most consequential industries.